Navigation Links
Variations in key gene predict cancer patients' risk for radiation-induced toxicity
Date:7/8/2014

(NEW YORK July 8, 2014) Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study published this week in Nature Genetics. The research team, which included researchers at the Icahn School of Medicine at Mount Sinai, found that variations in the TANC1 gene are associated with a greater risk for radiation-driven side effects in prostate cancer patients, which include incontinence, impotence and diarrhea.

The current results are based on a genome-wide association study, a type of study in which researchers examine numerous genetic variants to see if any of them are associated with a certain type of complication, which could sometimes emerge years after treatment was completed.

"Our findings, which were replicated in two additional patient groups, represent a significant step towards developing personalized treatment plans for prostate cancer patients," said Barry S. Rosenstein, PhD, Professor, Radiation Oncology, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, the lead Mount Sinai investigator on the study. "Within five years, through the use of a predictive genomic test that will be created using the data obtained in the recent study, it may be possible to optimize treatment for a large number of cancer patients."

For the study, Dr. Rosenstein and his team obtained blood samples from nearly 400 patients who were receiving radiotherapy treatment for prostate cancer. The blood samples were screened for roughly one million genetic markers, and each patient was monitored for at least two years to track incidents of side effects from the radiation. Data analysis showed which genetic markers were consistently associated with the development of complications following radiotherapy.

"The next step is to validate the results, and see if the same markers predict similar outcomes in patients with other forms of cancer," said Dr. Rosenstein. Using the genomic test being developed, treatment plans can be adjusted to minimize adverse effects thereby allowing for an improved quality life for many cancer survivors.


'/>"/>

Contact: David Slotnick
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. Small variations in genetic code can team up to have a bi
2. A mathematical perspective of seasonal variations in Lyme disease transmission
3. Tropical ecosystems regulate variations in Earths carbon dioxide levels
4. Mount Sinai study identifies new gene variations associated with heart rate
5. Even in same vineyard, different microbes may create variations in wine grapes
6. Gene variations linked to lung cancer susceptibility in Asian women
7. Variations of a single gene can lead to too much or too little growth, study shows
8. Fine-scale climate model projections predict malaria at local levels
9. Preconceptional factors in the prediction of fertility and the reproductive lifespan
10. Forelimb bone data predicts predator style
11. Decomposing logs show local factors undervalued in climate change predictions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced the appointment of ... surgeon, industry consultant, and private healthcare investor, to its ... healthcare leader with clinical and strategic experience at the ... Chairman and CEO. "As one of the world,s leading ...
(Date:12/2/2016)... ... 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing the ... chain-of-custody solution for tracking and securing medications at booth 676 at the ASHP ... Aerocom has a proven solution for tracking medications via its system from pharmacy ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a ... their recent FDA Class II 510(k) clearance for their flagship medical device, SimplECG. ... remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies have ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 ... Billion by 2021, growing at a CAGR of 7.3% during the ... segment while hospitals and diagnostic laboratories segment accounted for the largest ... ... Complete report on global immunohistochemistry (IHC) market spread across 225 ...
Breaking Biology Technology: